Key takeaways
Psychedelics are gaining mainstream acceptance: Growing research and regulatory momentum are pushing psychedelic therapies closer to becoming approved treatments for mental health conditions like depression, anxiety, and PTSD.
Different business models offer unique opportunities: Companies like MindMed focus on drug development, Numinus Wellness provides therapy services, and Compass Pathways leads in clinical trials—offering investors a range of ways to gain exposure to the sector.
High risk, high reward industry: While the potential for groundbreaking treatments is massive, regulatory hurdles, clinical trial outcomes, and funding challenges make psychedelic stocks highly speculative investments, and should not be invested in without exceptionally high tolerance for risk.
3 stocks I like better than the ones on this list.In This Article
- Definium Therapeutics, Inc. (DFTX)
- COMPASS Pathways plc (CMPS)
- NRX Pharmaceuticals, Inc. (NRXP)
- Incannex Healthcare Inc. (IXHL)
- Helus Pharma (HELP)
- Psyence Biomedical Ltd. (PBM)
⚠ Volatility Notice: This article contains micro-cap and/or small-cap stocks (under $1B market cap). These companies tend to have lower trading volume and can experience significantly higher price volatility than large-cap stocks. Please exercise additional caution and conduct thorough due diligence before investing.
Definium Therapeutics, Inc. (NASDAQ: DFTX)
$34.40
Overall Grade4.1 / 10
Definium Therapeutics, Inc., formerly known as Mind Medicine (MindMed) Inc., is a clinical-stage biopharmaceutical company headquartered in New York. The company is dedicated to developing a new generation of treatments for brain health disorders by leveraging the therapeutic potential of psychedelic and psychoplastogenic drugs...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-
P/B-
P/S-
P/FCF-
FCF Yield-
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)-
Revenue 5yr-
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$4.7B
Dividend Yield-
Operating Margin-
ROE-
Interest Coverage-
Competitive Edge
- MM120, the LSD-based candidate for generalised anxiety disorder, targets an indication where the last novel mechanism approved was decades ago and where SSRIs leave a large treated-but-unresponsive population. That is a commercial gap a differentiated mechanism can fill without displacing an entrenched incumbent.
- The company owns a proprietary form of the molecule rather than relying on a naturally occurring compound, which is what makes composition-of-matter protection and orphan-style exclusivity arguments possible. Without that, a psychedelic asset is very hard to defend against compounders and generic entrants.
- FDA Breakthrough Therapy designation in GAD buys rolling review and direct agency contact, which compresses the gap between readout and filing. For a single-asset company, months of review time are worth real money because they are months of burn avoided.
- The rebrand away from MindMed distances the story from the retail psychedelics trade of 2020 and 2021 and toward a conventional CNS drug developer. That matters for the institutional buyer base that will have to absorb the next financing.
- A durable-response profile, where a small number of supervised doses produce months of effect, changes the payer conversation from daily-pill price comparison to episode-of-care economics. That is the mechanism by which a novel CNS drug can command price rather than compete on it.
By the Numbers
- Altman Z of 16.09 is not a solvency signal here, it is a read on the balance sheet mix: a company with almost no debt, no inventory and a large cash pile relative to a small asset base. It says the $5.4B equity value is not sitting on top of a funding cliff in the next few quarters.
- The P/B of 5.90 against a 5-year average of 2.47 is the only multiple in this dataset that carries information, since every earnings-based multiple is negative and therefore meaningless. Book value is essentially cash, so the market is paying roughly six times remaining cash for the pipeline option.
- Momentum grade of 7.9 rests on real breadth, not one gap: nine of the last twelve months positive and a 117% six-month total return. That is a re-rating spread across the year rather than a single readthrough event, which usually means the shareholder base has been rebuilt at higher prices.
- The three-year compound return of 110.3% a year against a five-year figure of 2.5% brackets the 95% drawdown inside the window. Anyone underwriting this today is underwriting the post-2022 base, not the original MindMed cost basis.
- Analyst EPS estimates walk from -$3.17 in FY2026 to +$1.10 in FY2029 and +$3.81 in FY2030, with the revenue line going from zero to $1.16B. Thirteen analysts covering a pre-revenue name means the sell side is modelling approval, not just enrolment.
Risk Factors
- Stock compensation of $28.2M against zero revenue is the entire compensation economics of the business. Against an estimated FY2026 net loss of $276M it is roughly a tenth of the burn, so a meaningful slice of cash preservation is being financed by handing out equity at a $5.4B valuation.
- Buyback yield of -19.9% is share issuance, not repurchase, and TTM repurchases are zero. Shareholders funded the last twelve months by absorbing roughly a fifth dilution, and the balance sheet findings note borrowings exceeded repayments in each of the last three years, so both equity and debt taps were open.
- The company beat analyst estimates in only 2 of the last 8 quarters and missed by 39% on average. For a pre-revenue biotech those misses are cost and timing misses, which is the tell that trial spend and enrolment schedules are running ahead of what management communicates.
- Operating cash outflow widened between FY2022 and FY2025 rather than stabilising, earning a Growth grade of 2 out of 10. Burn accelerating into Phase 3 is normal, but it removes the option of waiting out a closed financing window.
- Analysts sit 43% apart on next year's number and the company has posted 6 loss years in the last decade. A 43% spread on a loss estimate means the covering analysts do not agree on the spend profile, let alone the probability of approval.
COMPASS Pathways plc (NASDAQ: CMPS)
$11.35
Overall Grade3.6 / 10
COMPASS Pathways plc is a clinical-stage pharmaceutical company that develops psychedelic therapies for serious mental health challenges. The company's flagship candidate, COMP360, is a proprietary, high-purity synthetic psilocybin formulation designed to be administered in conjunction with psychological support...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-3.1
P/B22.7
P/S-
P/FCF-11.9
FCF Yield-8.4%
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)+151.1%
Revenue 5yr-
EPS 5yr+12.1%
FCF 5yr+20.9%
Fundamentals
Market Cap$1.6B
Dividend Yield-
Operating Margin-
ROE-319.1%
Interest Coverage-
Competitive Edge
- COMP360 is the most clinically advanced synthetic psilocybin candidate in Phase 3 for treatment-resistant depression, giving Compass a multi-year head start over most psychedelic-therapy peers still in Phase 2.
- A proprietary, high-purity synthetic formulation creates a manufacturing and regulatory data moat that generic psilocybin producers cannot easily replicate once patents and trial data are established.
- Pipeline optionality across depression, PTSD, and anorexia nervosa gives multiple shots on goal from a single molecule, reducing reliance on one indication's trial outcome.
- Insider ownership of 7.6% is adequate alignment for a clinical-stage biotech at this market cap, keeping management exposed to the same dilution and binary trial risk as shareholders.
By the Numbers
- Cash per share sits at $3.82 against a $13.14 stock price, and net debt is negative $378.7 million, giving the company multiple years of runway before it needs to tap markets again at distressed prices.
- Total shareholder yield of 50% looks unusual for a cash-burning biotech, but it reflects share repurchases layered on top of large capital raises, not organic cash generation.
- Six-month total return of 187% and a position at the 52-week high show the market is pricing in real probability of Phase 3 readouts succeeding, not just baseline drug-development risk.
- Analysts model revenue scaling from $2.0 million in FY2026 to $202.3 million by FY2028, implying a commercial launch is expected inside the forecast window rather than pushed out indefinitely.
Risk Factors
- Shares outstanding grew 38.2% year over year and 41% annually between FY2020 and FY2025, meaning any per-share value creation has to first overcome a rapidly expanding denominator.
- EV/EBITDA of -9.2x is 290% above its own 5-year average of -2.4x and P/FCF of -12.7x is 184% above its 5-year average of -4.5x, so the stock is unusually expensive relative to its own trading history even before considering it has no earnings.
- Unlevered FCF of negative $178.1 million against a market cap of $2.05 billion means the company is burning close to 9% of its market value a year with no revenue offsetting it.
- FCF growth fell 15% year over year even as the 5-year FCF CAGR shows improvement at 22.5%, so the most recent trend is moving the wrong direction versus the longer arc.
- Buyback yield of -17.2% is a negative shareholder yield metric here, meaning net share issuance is overwhelming any repurchase activity despite the $239,000 buyback figure on the books.
NRX Pharmaceuticals, Inc. (NASDAQ: NRXP)
$2.70
Overall Grade3.1 / 10
NRx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-7.4
P/B-1,038.3
P/S52.0
P/FCF-8.9
FCF Yield-11.2%
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)-75.4%
Revenue 5yr-
EPS 5yr-63.6%
FCF 5yr-
Fundamentals
Market Cap$123M
Dividend Yield-
Operating Margin-586.2%
ROE+191.4%
Interest Coverage-17.4x
Competitive Edge
- NRX-100 is preservative-free IV ketamine seeking an approved label for suicidal depression, a use already widespread off-label through compounded and 503B supply. Converting an existing clinical habit into an on-label product is a far shorter commercial path than creating demand from scratch.
- Ketamine's active ingredient is off patent, so the defensible asset is the NDA, the preservative-free formulation and any regulatory exclusivity, not composition of matter. That shifts the moat from chemistry to FDA paperwork, which is cheaper to build but must be held against 503B compounders.
- The HOPE Therapeutics clinic rollup gives NRx a route to control the channel that dispenses its own drug, capturing both the product margin and the interventional psychiatry service fee. Few micro-cap developers own distribution for the molecule they are filing.
- NRX-101 targets suicidal bipolar depression, a population explicitly excluded from most antidepressant trials because of suicide risk. Sparse competitive interest from Johnson & Johnson's Spravato franchise or generic lurasidone makers leaves the indication largely uncontested.
- Breakthrough and fast-track style designations in suicidality shorten review timelines and let a company this size go head to head with far better funded CNS programs on calendar rather than on budget.
By the Numbers
- Net cash of $25.9M against just $834K of total debt means the capital structure carries no refinancing risk. For a clinical-stage name, the entire question is runway, not solvency, and there is no lender who can force the issue.
- The loss per share narrowed from prior levels with EBIT improving 52.7% year over year and EBITDA improving 49.0%, so the burn is shrinking even as programs advance. Operating discipline is visible in the cash flow, not just the pipeline slides.
- Stock compensation of $439K on TTM revenue of $1.2M is small in absolute dollars for a Nasdaq biotech. Dilution here is coming from equity raises, not from an insider pay grab, which is a meaningfully different problem to solve.
- Six-month total return of 58% with the stock still 28% below its 52-week high shows the re-rating is underway but not finished pricing the HOPE clinic and NRX-100 filings. Momentum grade of 5.9 is the strongest non-debt score on the card.
- Insiders own roughly 11%, including an officer who is also a major holder. In a company that has diluted at 44% a year since FY2020, that alignment at least puts management on the same side of the raise as outside holders.
Risk Factors
- Share count grew 110% in the last year and compounded at 44% a year from FY2020 to FY2025. Revenue per share of $0.112 is the number that matters: even a successful launch has to clear a far larger equity base than the original holders owned.
- Net cash covers roughly 0.8 years of cash burn at the current rate, with FCF of negative $0.65 per share. Another financing is arithmetically required well before the FY2027 revenue estimate of $100.2M could arrive.
- The current ratio of 0.86 with a cash ratio of 0.79 means almost all current assets are cash, and they still do not cover current liabilities. DPO of 366 days says vendors are effectively financing the company, which is a funding tell, not a working capital win.
- P/S of 42.4x sits on TTM revenue of $1.2M, so the multiple is a rounding artifact of a near-zero denominator. The real valuation anchor is the FY2027 revenue estimate of $100.2M, which is sourced from only two analysts.
- Max drawdown of 99% over five years, 264 trading days peak to trough and not yet recovered, alongside 54% annualised downside deviation and 12 days beyond 10% moves in the past year. The Risk grade of 1.2 is not an outlier reading, it is the base case here.
Incannex Healthcare Inc. (NASDAQ: IXHL)
$2.93
Overall Grade2.7 / 10
Incannex Healthcare Inc. operates primarily in the research and development of novel pharmaceutical products...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-2.3
P/B0.7
P/S-
P/FCF-3.7
FCF Yield-27.3%
Growth & Outlook
Rev Growth (YoY)-100.0%
EPS Growth (YoY)-95.9%
Revenue 5yr-100.0%
EPS 5yr-42.4%
FCF 5yr+4.0%
Fundamentals
Market Cap$36M
Dividend Yield-
Operating Margin-
ROE-47.8%
Interest Coverage-81.1x
Competitive Edge
- IHL-42X targets obstructive sleep apnea, where the only approved drug option is Eli Lilly's tirzepatide for OSA with obesity. A cheap oral fixed-dose combination that works in non-obese patients and those who reject CPAP addresses a gap GLP-1s do not cover.
- Both lead assets combine drugs already known to regulators, dronabinol with acetazolamide, and cannabidiol with hydroxychloroquine. Repurposing approved molecules shortens the toxicology package and lowers the chance of a surprise safety hold compared with a novel chemical entity.
- PSX-001 in generalised anxiety disorder puts the company alongside Compass Pathways and Usona in psychedelics, but in an indication with far less crowding than treatment-resistant depression. Differentiated indication choice matters more than molecule novelty in this field.
- The redomicile from Australia to a Delaware parent on Nasdaq widens access to US institutional capital and index inclusion that an ASX-only listing would not reach, which matters for a company whose only real product is its ability to fund the next trial.
- Zero debt and no partnership encumbrances mean full ownership of all three programs. If any readout is positive, the licensing negotiation happens with no prior claims on the economics.
By the Numbers
- Cash per share of $8.02 sits against a $3.44 share price, so the market is pricing the enterprise at less than the cash on hand. Net cash of $74.3M with total debt of just $114K means no creditor can force the timeline on IHL-42X or PSX-001.
- Book value per share of $8.11 is entirely tangible, intangibles are zero percent of assets. There is no goodwill from prior deals sitting on the balance sheet waiting to be written down, which is unusual for a clinical-stage name built through restructuring.
- Cash burn is running roughly $25.5M a year on unlevered FCF, against $74.3M of net cash. That is close to three years of runway at the current pace without another raise, which is longer than most Phase 2/3 biotechs carry.
- Current ratio of 41.56x and quick ratio of 41.35x mean working capital is almost entirely cash, with no receivables or inventory drag. The Balance Sheet grade of 6.3 out of 10 is held down by the operating losses, not by the capital structure itself.
- Insiders own 21% of the company, which is high for a Nasdaq-listed clinical-stage developer and means the people setting the trial timetable carry the dilution cost alongside outside holders.
Risk Factors
- Share count grew 38% a year between FY2020 and FY2025 and 14.5x in the last year alone. Total shareholder yield of -6833% is dilution, not capital return, and the Shareholder Returns grade of 0 out of 10 reflects that exactly.
- Stock compensation of $7.67M over the trailing twelve months exceeds trailing revenue of $86K by roughly 89 times and equals almost a third of the annual cash burn. Non-cash pay at that scale keeps compounding the share count regardless of trial outcomes.
- Trailing EPS of -$40.50 against analyst estimates of -$1.22 for FY2027 is not an operating turnaround, it is the arithmetic of a vastly larger share base. The loss per share shrinks because the denominator exploded.
- The FY2027 revenue estimate of $40.0M collapses to $53.4K in FY2028 on a single analyst's numbers. A forecast that swings by three orders of magnitude between consecutive years is not a forecast anyone should underwrite.
- Maximum drawdown of 100% over five years with 105% annualised downside deviation, 22 days moving beyond 10% in the last year, and the stock still 82% below its 52-week high. The Risk grade of 0.9 out of 10 is the single worst mark on this report.
Helus Pharma (NASDAQ: HELP)
$10.50
Overall Grade2.6 / 10
Helus Pharma Inc., formerly known as Cybin Inc., is a clinical-stage pharmaceutical company based in Canada that develops novel serotonergic agonists and psychedelic-based therapeutics for mental health conditions. The company engineers proprietary synthetic molecules designed to target specific serotonin receptors, aiming to treat major depressive disorder and generalized anxiety disorder...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-1.6
P/B1.7
P/S-
P/FCF-2.9
FCF Yield-34.9%
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)-8.0%
Revenue 5yr-
EPS 5yr-16.0%
FCF 5yr+46.7%
Fundamentals
Market Cap$862M
Dividend Yield-
Operating Margin-
ROE-86.9%
Interest Coverage-
Competitive Edge
- Lead asset HLP003 is a deuterated psilocin analog in Phase 3 for major depressive disorder, deuteration is a specific mechanism to slow metabolic clearance and extend half-life, a real differentiation lever against first-generation psilocybin compounds.
- Operating with zero total debt gives management full flexibility to fund trials through equity or partnership without covenant constraints or refinancing risk clouding a binary readout.
- The company sits in the serotonergic/psychedelic therapeutics niche, which has attracted FDA breakthrough therapy designations for peers, a regulatory pathway that can compress time to market versus standard CNS drug review.
- Insider buying activity ($8 million, 8 separate purchases) in a stock that fell sharply over five years suggests people closest to the trial data see value that the market, focused on dilution, is discounting too hard.
By the Numbers
- Current ratio of 10.97x and cash per share of $2.68 against zero total debt means this company has years of runway at current burn before needing to tap capital markets on distressed terms.
- FCF to net income conversion of 0.83x is unusually clean for a clinical-stage biotech, suggesting the net loss isn't being masked or inflated by non-cash items beyond normal SBC.
- Net debt is negative $166.4 million (net cash), and net debt to EBITDA of 1.0x is only positive because EBITDA itself is negative, this is a balance sheet built to survive trial setbacks.
- Insiders bought $8 million in open market purchases across 8 transactions over the last year, more than they sold, a real signal in a stock down 32% annualized over five years.
- Analysts model EBIT flipping positive by the FY4 estimate ($18.4 million) and scaling to $148.6 million by FY5, implying the Phase 3 program is expected to clear a commercial inflection, not just a regulatory one.
Risk Factors
- Shares outstanding grew 103.27% year over year (shares_growth_1y of 1.03), meaning the share count roughly doubled, this is why buyback yield of -24.4% is irrelevant noise against raw dilution.
- EV/Sales of 9,920.7x and P/S of 15,570.1x are a function of near-zero revenue, not demand, revenue per share is effectively $0, these multiples cannot be used to judge value.
- TTM stock compensation of $21.7 million against a company with no meaningful revenue is a material dilution engine, compounding the share count growth already seen.
- Analyst estimates show revenue falling from $31.7 million in FY1 to $9.3 million in FY2, a 71% drop, before rebounding to $190.2 million in FY3, a path that assumes a single event (approval or milestone payment) rather than steady commercial ramp.
- FCF growth of 70.5% YoY and 56.6% over 3 years looks positive only because the FCF burn is shrinking off a worse base, unlevered FCF remains negative $142.3 million in absolute terms.
Psyence Biomedical Ltd. (NASDAQ: PBM)
$4.55
Overall Grade2.6 / 10
Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company focused on developing nature-derived psychedelic therapeutics for mental health and addiction disorders...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-
P/B-
P/S-
P/FCF-
FCF Yield-
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)-
Revenue 5yr-
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$19M
Dividend Yield-
Operating Margin-
ROE-
Interest Coverage-
Competitive Edge
- PEX010 uses naturally sourced psilocybin supplied through an established GMP route, which sidesteps the synthesis and scale-up risk that synthetic peers like Compass Pathways and Cybin carry, and can shorten the CMC section of a filing.
- Targeting adjustment disorder in patients with an incurable cancer diagnosis is a narrow, poorly served indication with a plausible orphan-style regulatory path, rather than competing head-on with Compass in treatment-resistant depression where the trial cost is far larger.
- Running the Phase IIb in Australia gives access to the R&D tax incentive rebate and the TGA Authorised Prescriber scheme, which since 2023 has allowed psilocybin prescribing for specific indications. That is a real commercial bridge no US-only developer has.
- A $25M market cap on a Phase IIb asset means any positive readout is measured against almost no embedded expectation. The asymmetry runs in the owner's favour if the trial reads out, which is the only genuine argument for the equity.
By the Numbers
- Altman Z of 19.86 sits in the excellent band, which for a pre-revenue biotech says the balance sheet is mostly cash and near-cash against tiny liabilities rather than signalling any earnings strength. It is a liquidity artefact, not a business quality signal.
- TTM stock compensation of just $155k against a $24.9M market cap is a rounding error at roughly 0.6% of the cap. Most clinical-stage names of this size burn multiples of that on equity grants, so the dilution here is coming from financings, not payroll.
- Price to book of 1.47x means the market is only paying about 47 cents above net assets for the entire PEX010 program. For a Phase IIb asset, that is close to a cash-and-carry valuation with the pipeline valued near zero.
- Six-month total return of 180% against a stock still 78% below its 52-week high shows the move is a recovery off a washed-out base, not a new trend from strength. The Momentum grade of 4.3 captures that split honestly.
Risk Factors
- Every valuation multiple is negative and worse than its own five-year average: P/E at -0.5x versus -0.1x, EV/EBITDA at -2.8x versus -0.7x, P/FCF at -3.1x versus -0.8x. Negative multiples do not measure cheapness, they measure how fast losses are widening relative to the equity value.
- Cash from operations was negative at both ends of FY2023 to FY2026 and the shortfall got bigger over the window. Burn is accelerating while the trial is still running, which means the next financing is a question of when, not if.
- Buyback yield of -0.56% is share issuance, not repurchase, and it sits alongside a reverse split inside three years. The dilution cap of 2 on the Share Dilution measure tells you the share count has already run away from holders once.
- Borrowings exceeded repayments in each of the last three years, driving the Balance Sheet grade to 1.8. A clinical-stage company funding trials with debt rather than equity is trading dilution today for a harder covenant problem later.
- Downside deviation of 102% annualised with 29 days beyond 10% moves in the last year, and a maximum drawdown of 100% over 353 days that has not recovered. RSI at 83 after a 61% one-month move is the kind of setup that tends to give back a large share of the gain.
